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Summary  
Background 
Psychosis is a common presenting feature in antibody-mediated encephalitis, where 
prompt recognition and treatment usually leads to remission. It is not known whether 
people with circumscribed schizophrenia-like illnesses also have these antibodies, 
especially antibodies against the NMDA receptor (NMDAR), more commonly than 
do healthy controls.  
Methods 
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We recruited patients with a first episode of psychosis and less than 6 weeks of 
treatment with antipsychotic medication from mental health services. We completed 
standardised symptoms rating scales (PANSS, ACE-III, GAF) at baseline, and tested 
serum for antibodies against NMDAR and four other neuronal cell surface targets: 
LGI1, CASPR2, GABAA receptor (GABAAR) and AMPA receptor (AMPAR) using 
live cell based assays. Treating clinicians assessed outcomes at 6 months. We 
recruited healthy controls with similar characteristics in age, gender and ethnic origin 
as the cases.  
Findings 
20 (8.8%) of 228 first-episode psychosis patients had serum antibodies against one or 
more of the neuronal cell surface antibodies, compared with 4 (3.8%) of 105 controls 
which was not significant ((odds ratio (OR) 2·4 (95%CI 0·8 - 7·3) unadjusted). These 
associations remained non-significant when adjusted for current cigarette smoking, 
alcohol consumption and illicit drug use. 7 (3·1%) of 228 first-episode psychosis 
patients had NMDAR antibodies, compared with 0/105 controls. The other individual 
antibodies were not different between groups. Antibody-positive patients had lower 
PANSS positive and PANSS total scores, and catatonia scores, than patients without 
antibodies. Patients had comparable scores on other PANSS items, ACE-III and GAF 
at baseline, and there was no difference in outcomes.   
Interpretation 
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A proportion of patients with first episode psychosis have antibodies against 
NMDARs that might be relevant to their illness. These patients do not differ from 
those without NMDAR antibodies in clinical characteristics. Therefore our study 
suggests that the only way to detect patients with these potentially pathogenic 
antibodies is to screen all those with first-episode psychosis at first presentation. 
Funding 
MRC 
 
Research in context 
Evidence before this study 
We searched MEDLINE up to August 2016 for all studies on the prevalence of 
neuronal cell surface antibodies in patients with psychosis. We used search terms 
“antibod*” AND “psychosis”OR”schiz*” AND “NMDA*”OR”N-methyl-D-aspartate 
receptor” OR “LGI1” OR “CASPR2” OR “mGluR5” OR “AMPA*” OR “GABAA*” 
OR “GABAB”. We excluded non-English language articles. Several studies have 
examined the prevalence of serum NMDA receptor antibodies, with one systematic 
review and meta-analysis of 9 studies, including 3387 participants showing a three 
times greater (odds ratio 3·1) NMDA receptor antibody positivity in patients with 
schizophrenia or schizoaffective disorder, bipolar affective disorder or major 
  
 
4 
 
 
 
depressive disorder compared with controls. Subsequent studies have reported 
varying results. One study in children found 11.6% of 43 NMDA receptor IgG 
antibodies in those with psychosis, and none in 43 healthy or disease controls.  The 
largest studies failed to find any seropositive psychosis cases or found equivalent 
prevalence in healthy controls. One study found similar seropositivity for LGI1 and 
CASPR2 antibodies in patients with established schizophrenia and healthy controls. 
Another found no antibodies against AMPA receptor in 459 participants with 
psychiatric illness or healthy controls.  No studies have examined the prevalence of 
GABAA  receptor antibodies in patients with psychosis.  
Added value of this study 
We found no overall differences in prevalence of antibodies against neuronal cell 
surface proteins in the serum of well-characterised patients with first episode 
psychosis and with less than 6 weeks medication compared with a matched healthy 
control sample. NMDAR antibodies were present in the serum of patients with first-
episode psychosis whereas none were detected in controls. This provides a better 
estimate of the prevalence of neuronal cell surface antibodies associated with the 
onset of psychotic illness. 
Implications of all the available evidence 
Our finding that NMDA receptor  antibodies can be detected in the serum of patients 
with a first episode psychosis at a higher rate than controls supports existing evidence 
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that reduced activity of the NMDA receptor has an important role in schizophrenia.  
Antibodies to the NMDAR at the onset of illness may be the basis for these findings 
in some patients. Patients with these antibodies might respond to treatment with 
immunotherapy and screening of patients with first-episode psychosis is therefore 
suggested. 
 
Introduction 
Autoantibodies to neuronal cell surface receptors and related proteins have been 
described in association with encephalitic syndromes that frequently include 
psychiatric symptoms, usually psychosis, as a prominent part of the phenotype. Anti-
N-methyl-d-aspartate receptor (NMDAR) encephalitis, first described in 2007,1 is the 
most common of these. It is a multistage encephalitis caused by antibodies to the 
GluN1(NR1) subunit of the NMDAR which presents initially with psychiatric 
symptoms in over two thirds of patients, before recognition of neurological symptoms 
which include cognitive deficits, seizures, autonomic instability and movement 
disorder . 2  
Several autoimmune encephalitides have subsequently been identified associated with 
autoantibodies to other cell surface antigens , including LGI1,3 CASPR2,3 AMPAR4 
and GABAAR.
5 Psychiatric or behavioural manifestations are commonly described, 
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and there are occasional case reports of patients with purely psychiatric presentations 
with these antibodies. 5,6  
In autoimmune encephalitis associated with VGKC-complex antibodies, the 
antibodies are usually directed against the neuronal surface antigens LGI1 and 
CASPR2, which are components of the VGKC complex: these antibodies are thought 
to be pathogenic. 3 There are further cases when the VGKC-complex antibodies do 
not bind LGI1 or CASPR2.7,8 It is likely that some bind intracellular, non-pathogenic, 
epitopes on the VGKC-complex, and are therefore not clinically relevant, 7 although 
one study in children suggests that they may still be a marker for immune responsive 
neuroinflammatory conditions.8 
In general, for these encephalitides, early treatment with first line (e.g. steroids, 
plasmapheresis and/or intravenous immunoglobulins) or second-line (e.g. rituximab 
or cyclophosphamide) immunotherapy is associated with good outcome and many 
patients are able to return to a premorbid status. 9,10 
Following initial recognition that these syndromes can cause psychosis as a prelude to 
a wider encephalitic picture, there has been considerable interest as to whether these 
autoantibodies are associated with psychotic symptoms without the emergence of 
other features of encephalitis, in patients presenting to psychiatric services. 
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In 2010 we identified serum antibodies to the NMDAR or VGKC-complex in 3 out of 
43 (6·3% (95% CI 1·9-16·5%) of patients presenting to a first episode psychosis 
service.11 A systematic review and meta-analysis showed an odds ratio (OR) of 3·1 
for serum NMDAR antibody positivity in patients with schizophrenia or 
schizoaffective disorder, bipolar affective disorder or major depressive disorder 
compared with controls,12 and a recent study of serum NMDAR antibodies in children 
has confirmed this finding.32 However, there is considerable heterogeneity in terms of 
diagnosis, duration of illness, and the assay method used for detection of antibodies in 
these studies, and some large case-control studies have found no difference between 
patients with psychosis and controls in rates of NMDAR,13,14,15 or LGI1/CASPR215 
antibodies in serum.  
In this study we aimed to provide a better estimate of the prevalence of NMDAR and 
other disease-relevant neuronal cell surface antibodies in the serum of patients with a 
first episode psychosis, compared to a group of healthy controls with similar age, 
gender and ethnicity characteristics. Given the association between autoantibody-
mediated CNS disease and cognitive impairment 16,17 and to investigate further the 
possibility that autoantibody positivity might delineate a distinct phenotypic subgroup 
of patients with psychosis, we also aimed to characterise the clinical and cognitive 
profile of our subjects. We measured antibodies in serum rather than CSF both to 
align with clinical practice in the UK, and because of the experience in encephalitis, 
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where antibodies are detected at a higher rate in serum than CSF, especially early in 
the course of illness.2 
While there is evidence that non-IgG antibodies (ie IgM, IgA) may have pathogenic 
potential within the CNS,18 these are very uncommonly detected with live cell assays 
(AV, LJ unpublished data) and the study was restricted to IgG antibodies only. 
Methods 
Study design and participants 
35 sites across England recruited patients experiencing a first episode of psychosis 
who were in contact with early intervention, community, or inpatient mental health 
services. Inclusion criteria comprised age between 14 and 35 years, less than 6 weeks 
on antipsychotic medication, and a score of 4 or more on at least one of the following 
Positive and Negative Syndrome Scale (PANSS)19   positive items: 1 (Delusions), 3 
(Hallucinations), 5 (Grandiosity), 6 (Suspiciousness), or PANSS General item 9 
(Unusual Thought Content). Exclusion criteria included: suspected drug induced 
psychosis or the presence of neurological disorder (eg head injury, multiple sclerosis). 
The Local Research Ethics Committee approved the patient study, reference 
12/EE/0307.  
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Control participants were recruited from the general population in Cambridge, UK as 
part of a separate study (Local Research Ethics Committee reference 08/H0308/5). 
Inclusion criteria included age over 16 years, with no personal or family history of 
mental illness. The control sample was similar in age, gender and ethnicity to a 
typical sample of first episode psychosis patients, and was similar to the current 
sample on these demographics (Table 1).  
Procedures 
Written informed consent was obtained from every participant. Patients were assessed 
at a single baseline assessment session with the following clinical measures: 
Psychotic symptoms: Positive and Negative Syndrome Scale (PANSS)19 with 
positive, negative and general psychopathology symptoms sub-scores; general level 
of functioning for people with psychiatric disorders: Global Assessment of 
Functioning (GAF),20 catatonic symptoms: Bush-Francis Catatonia Rating Scale 
(CRS), 21 brief cognitive assessment: Addenbrookes Cognitive Exam-III (ACE-III). 22 
PANSS rating concordance was assessed: Research assistants involved in data 
collection rated a standardised video of a PANSS interview. Inter-rater reliability was 
good: each RA score was within 1 S.D of the mean. 6 month outcomes were assessed 
from notes by treating clinicians, including GAF and illness course. 
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All patients and controls gave a venous blood sample; patient samples were taken at 
initial clinical assessment.  
 
Antibody assays 
Autoantibody testing was undertaken in Oxford using assays in routine clinical use. 
2,23 A live cell-based assay was used for the detection of IgG antibodies to NR1 
subunit of NMDAR, the VGKC-complex associated proteins LGI1 and CASPR2, α1 
and γ2 subunits of GABAAR and AMPAR, as described previously. 3,5,23 Binding to 
the cell membrane was scored by fluorescence microscopy, with a visual score 
ranging from 0-4.2  The titre of each antibody was given as the dilution of serum 
providing a score of 1. All assays were repeated, checked for IgG specificity, as for 
routine diagnosis, and scored separately and blind to diagnosis, on each occasion. 
VGKC-complex antibodies were measured using a radio-immunoprecipitation assay 
of VGKC complex proteins labelled with 125I-a-dendrotoxin and precipitated with 
patient sera. 23  
Anti-nuclear antibodies (ANA), as an additional test of autoimmunity, were measured 
by direct immunofluorescence. 
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Statistical Analyses 
We analysed data using SPSS version 22. We used t-tests to compare age andχ2 tests 
to compare categorical demographic and lifestyle variables between first-episode 
psychosis patients and controls and the prevalence of neuronal cell surface antibodies. 
We used Odds Ratios (unadjusted, and adjusted for smoking, alcohol and illicit drug 
use) to compare the prevalence of antibodies between first-episode psychosis patients 
and controls. Likelihood ratios (unadjusted) were used to compare the prevalence of 
NMDAR and LGI1, as odds ratios could not be calculated. because of null values in 
the control group. 
  We used χ  2 tests and t-tests (or Mann-Whitney U tests with non-normally 
distributed data) to test for associations between clinical and cognitive test variables 
and antibody status in patients with first episode psychosis. For all analyses 
significance level was set at p=0.05. 
Results  
The 228 first episode patients and 105 healthy controls were similar in age, gender 
and ethnic origin (table 1). The youngest first-episode psychosis patient was aged 16 
years. Patients were more likely to be current cigarette smokers than controls (n=120 
(53%) of patients and n=16 (15%) of controls  (p<0.001)) and more likely to be 
current users of illicit drugs n=57(25%) patients compared with n=14(13%) controls 
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p=0.015, whereas control subjects were more likely to be current alcohol drinkers 
n=82 (78%) controls compared with n=105 (46%) patients (p<0.001%) 
On antibody testing 20 (8.8%) of first-episode psychosis patients were positive for 
any one neuronal cell surface antibody compared to 4 (3.8%) controls (table 2), but 
this difference was not significant.  Serum NMDAR antibodies were more prevalent 
in patients (n=7; 3.1%) than in controls (0, 0%, p=0·02). VGKC-complex antibodies 
were present in 11 (4.8%) patients and 3 (2.9%) controls (p=0.38). One patient was 
positive for both NMDAR and VGKC-complex antibodies. The first-episode 
psychosis patients and controls did not differ in the presence of serum antibodies 
against LGI1, CASPR2, and GABAAR antibodies (table 2). No patients or controls 
had AMPAR antibodies.   Overall, titres of those with positive antibodies were low 
(table 2). None of those with VGKC-complex antibodies had antibodies against LGI1 
or CASPR2.  
As the patient and control groups differed in rates of alcohol use, cigarette smoking 
and illicit drug use, adjusted odds ratios were calculated, group differences remained 
non-significant. 
None of the patients with neuronal antibodies had ANA antibodies, and there was no 
significant difference in ANA antibodies between controls 9 (8.6%) and patients (7 
(3.1%),  OR = 0·50 (0·2-1·4).  
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Clinical and cognitive phenotype 
The neuronal cell surface antibody positive and negative first-episode psychosis 
groups were compared on assessments of clinical and cognitive symptoms (table 3). 
Both groups had levels of psychotic symptoms that indicate a moderate level of 
illness (PANSS total 69.0-77·6), with antibody-positive patients having lower mean 
PANSS Positive scores (19·1 (sd 3·7)) than antibody-negative patients (21·8 (sd 6·1) 
p<0.01) and lower mean PANSS total  scores (69·0 (sd 17·2)) in antibody positive 
patients than antibody negative patients (77·6 (sd 17·8); p=0.05). Both groups had 
low levels of catatonia symptoms, with antibody-positive patients having lower total 
scores (mean 0·60 (sd 1·1) than antibody negative patients (mean 2·2 (sd 3·7), 
p<0.001). 
Both groups also had impairment in their cognitive functioning (mean ACE-III 81·8) 
and were moderately functionally impaired with mean GAF scores of around 50, but 
with no significant differences in these parameters between antibody-positive and 
antibody-negative groups (table 3).  
Outcome data  
Patients positive for autoantibodies were followed up 6 months after baseline 
assessment, to investigate clinical course and outcome. There was no significant 
difference in the number of increased contacts with mental health services (either 
hospital admission or treatment with a home treatment/crisis service) between the 
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antibody-positive patients (mean 0.4 (sd 0.6) and the antibody-negative patients 
(0.5(sd 0.7) p= 0.51) nor on the mean follow-up GAF ratings (antibody positive 
66.5(sd 15.5), antibody negative 63.4 (sd 15.7) p=0.52). There were no cases of 
encephalitis in the patients, or development of neurological symptoms, as assessed by 
their treating psychiatrist 
Discussion  
In the largest study so far examining the prevalence of neuronal cell surface 
antibodies in serum of patients with first-episode psychosis, we have shown that . 
NMDAR antibodies are more prevalent in patients with first-episode psychosis than 
in the healthy control group. The prevalence of antibodies against GABAAR, LGI1 
and VGKC-complex did not differ between the groups.  Odds ratios adjusted for 
current smoking, alcohol consumption and illicit drug use were also non-significant.   
There were no major differences in clinical phenotype between antibody- positive and 
antibody-negative cases, however patients who tested positive for neuronal cell 
surface antibodies scored significantly lower on PANSS positive items and PANSS 
total score, as well as the Catatonia rating scale.   
Our NMDAR antibody findings corroborate an earlier report11 and provide support for 
the many converging lines of research evidence suggesting that NMDAR 
hypofunction plays an important part in schizophrenia. 24 Susceptibility genes for 
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schizophrenia, both common and rare variants, are particularly associated with 
glutamatergic transmission and  with the adaptive immune system.25 Pharmacological 
blockade of NMDAR produces the full spectrum of symptoms seen in schizophrenia, 
as well as the neuropathological findings of reduced numbers of inhibitory 
GABAergic interneurons and reduced dendritic spine density that are compatible with 
a model of NMDAR blockade.24,26 Antibodies to the NMDAR at the onset of illness 
may be the basis for these findings in some patients. 
For all antibodies except VGKC-complex and ANA, a live cell-based assay was used 
to assess antibody status. In a live cell-based assay the serum to be tested for auto-
reactivity is incubated with live HEK293 cells, previously transfected with plasmids 
encoding the specific antigen subunit(s), before these cells are fixed.2 By contrast, 
both commercial assays and the assays performed by most other laboratories involve 
fixation and/or permeabilisation of cells before incubation with serum or CSF.27 It is 
not known what effects fixation and permeabilisation (and other inter-assay 
differences) may have on the relative sensitivities and specificities of these assays. 
This is particularly true when the assay is used in psychiatric populations where, 
unlike in some autoimmune CNS disorders, eg neuromyelitis optica,28 there is no 
well-established and clinically-defined group against which such sensitivity and 
specificity can be assessed independently of autoantibody status. It is likely, however, 
that in assays other than live cell-based assays, permeabilisation of the cell membrane 
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exposes intracellular antigens and so seropositivity might indicate the presence of 
antibodies that can bind intracellular epitopes; these antibodies would not be expected 
to be pathogenic. 
VGKC-complex antibody levels, as measured by radioimmunoassay, did not differ 
significantly between first-episode psychosis patients and controls, and none of those 
with VGKC-complex antibodies had antibodies against LGI1 or CASPR2. The 
relevance of these antibodies in psychosis is, therefore, uncertain, and a high level of 
VGKC-complex antibodies, by themselves, might not be clinically relevant in 
psychosis.  
In this study, antibody-positive patients had a lower level of catatonic and psychotic 
symptoms. The absolute difference in symptom scores was modest, and does not 
reflect clinically meaningful differences. However, it does contrast with a previous 
case series of patients with NMDAR antibodies and psychosis where patients were 
described as being more psychiatrically unwell, with more catatonia, cognitive 
impairment, and with adverse reactions to antipsychotics.29  These previous cases 
might  have been subject to selection bias, whereby clinicians preferentially requested 
the antibody test only if the patient presented with atypical features suggestive of 
encephalitis. 
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The prevalence of IgG antibodies detected in this study is higher than that described 
in most other groups of patients with either first-episode psychosis or longstanding 
illness (ranging from 0 to 1.6%13,14,15). A notable exception is a study in children with 
psychosis, tested a median of 5 weeks after onset of symptoms, which found 11.6% 
NMDAR IgG antibodies, with none in healthy or illness controls34. A possible 
explanation is the short length of treatment with antipsychotics in our group 
Antipsychotics have been shown to have immunomodulatory properties,30 even 
showing therapeutic promise in an animal model of autoimmune encephalitis.31 Some 
studies have detected IgM and IgA antibodies to neuronal targets, 14,15,32 but we did 
not specifically look for IgM or IgA antibodies in this study as previous attempts to 
demonstrate them on live NMDAR assays were unsuccessful (AV, LJ unpublished 
data). 
A limitation of the study is that we did not collect CSF, owing  to the impracticality of 
doing lumbar punctures in routine UK mental health settings. Detecting antibodies in 
CSF provides a more definitive indicator that they are having a central nervous 
system effect in that individual.  However a recent study has shown that antibodies 
that have crossed the blood brain barrier tend to bind to the brain, with the brain 
acting as an ‘immunoprecipitator’, and will therefore not be measurable in CSF.33 An 
absence of antibodies in CSF does not, therefore, prove that antibodies are not causing 
illness in that individual.    A further limitation is that antibody status was measured at 
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a single time-point only. We were therefore unable to establish whether, as is the case 
in many autoimmune diseases, autoreactivity precedes the development of symptoms. 
If this is the case, it is plausible that a ‘second hit’ causing disruption of the blood-
brain barrier would be required for pathogenic antibodies to access the CNS and 
affect neuronal function, as has been suggested elsewhere.15 We looked only at 
patients with first-episode psychosis. These antibodies might be associated with other 
acute or subacute onset neuropsychiatric disorders with overlapping features with 
encephalitis, such as depression, dementia, or acute confusional states. 
Further work is now required to establish the specificity and pathogenicity of these 
antibodies in the context of psychosis.  The demonstration that even a small 
proportion of cases of schizophrenia-like psychosis have an autoimmune basis would 
have important ramifications for nosology and  for treatment, since they might 
respond to immunotherapy rather than antipsychotics or psychological interventions. 
Our study suggests that, at present, the only way to detect patients with these 
potentially pathogenic antibodies is to screen all those with first-episode psychosis at 
first presentation. 
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